endometrial carcinoma
Conditions
Interventions
Non progesterone group:Lepraline for injection + letrozole tablets by mouth or Intrauterine Sustained release System of lepreterine + Levonorethistone for Injection
Oral high potency progesterone group:Oral high potency progesterone(Medroxyprogesterone acetate or Megesterone acetate)
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: A highly differentiated endometrioid carcinoma was pathologically diagnosed by endometrial biopsy, diagnostic curettage, or hysteroscopy (G1 G2 EC); Or complex endometrial dysplasia (CAH/EIN) Either initial treatment or recurrence could be included, and recurrence was defined as rediagnosis in utero 6 months after CR was obtained from previous treatment Membrane carcinoma Pelvic enhanced MRI was performed 2 weeks before treatment, and upper abdominal enhanced CT was used to evaluate the lesions limited to the endometrial layer, which was not visible Confirmed myometrium infiltration or extrauterine involvement; Under the age of 40, have fertility requirements, insist on preserving reproductive function; u Informed consent and signed informed consent; Compliance is good.
Exclusion criteria
Exclusion criteria: The pathological types of endometrioid carcinoma are non-endometrioid carcinoma, such as serous carcinoma, clear cell carcinoma, etc. Poorly differentiated or undifferentiated; Imaging examination indicated myoinfiltration, cervical involvement, myoinfiltration or extrauterine involvement. Patients with impaired liver function (aminotransferase increased to 2.5 times or more of the normal upper limit) and severely impaired renal function (muscle Anhydride clearance rate <30mL/min); Patients with other malignant tumors of reproductive system; Complicated with deep vein thrombosis, pulmonary embolism, myocardial infarction cerebral infarction and other diseases; Those with contraindications to pregnancy; Failure of previous progesterone therapy; Use of the tested drug within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Countries
China
Contacts
Public ContactCaodongyan
Peking Union Medical College Hospital
Outcome results
None listed